Head and neck squamous cell carcinoma in HIV, HBV and HCV seropositive patients - Prognosis and its predictors
Head and neck squamous cell carcinoma in HIV, HBV and HCV seropositive patients - Prognosis and its predictors
复制标题
DOI：
10.4103/jcrt.jcrt_166_19
复制
发表时间：
2020-04-01
影响因子：
1.3
通讯作者：
Prabhash, Kumar
中科院分区：
文献类型：
--
作者：
Nayyar, Supreet Singh;Thiagarajan, Shivakumar;Prabhash, Kumar
简介：接受头颈部鳞状细胞癌（HNSCC）治疗的患者也可能同时存在由HIV、HBV和HCV（血清阳性）引起的病毒感染。关于这些合并病毒感染（血清阳性HNSCC）患者的临床表现和治疗结局的文献很少。我们进行了这项研究，以评估血清阳性HNSCC患者的临床表现和治疗结果（总生存期[OS]和疾病特异性生存期[DSS]）。方法：这是一项回顾性队列研究，针对2012年至2014年在我中心登记的血清阳性HNSCC患者。病毒感染是通过患者血液样本中存在这些病毒的抗体来鉴定的。结果：在登记的19，137名HNSCC患者中，有156名患者感染了HBV、HCV和/或HIV。其中，HBV感染最常见（n = 86/156，55.1%），其次是HIV感染（n = 36/156，23.1%）和HCV感染（n = 29/156，18.6%）。口腔是最常见的受累部位。这些患者中的大多数处于晚期（晚期T分期- 71.8%和淋巴结阳性- 62.2%）。大多数患者接受了治愈性治疗（65.4%）。这些同时存在HIV、HBV和HCV感染的HNSCC患者的3年OS分别为60%、62.6%和57.5%，3年DSS分别为58.8%、78.6%和53.8%。结论：血清学阳性的HNSCC患者通常出现在晚期，但如果治疗得当，生存率很高。
Introduction: Patients receiving treatment for head-and-neck squamous cell carcinoma (HNSCC) also may have coexisting viral infections caused by HIV, HBV, and HCV (seropositive). There is scarce literature regarding the clinical presentation and treatment outcomes for these patients with coexisting viral infections (seropositive HNSCC). We conducted this study to assess the clinical presentation and treatment outcomes (overall survival [OS] and disease-specific survival [DSS]) of seropositive HNSCC patients. Methodology: This was a retrospective cohort study on seropositive HNSCC patients registered at our center from 2012 to 2014. The viral infections were identified by the presence of the antibodies to these viruses in the patient's blood samples. Results: Out of the 19,137 HNSCC patients registered, 156 patients had HBV, HCV, and/or HIV infection. Among these, HBV infection was the most common (n = 86/156, 55.1%) followed by HIV infection (n = 36/156, 23.1%) and HCV infection (n = 29/156, 18.6%). The oral cavity was the most common subsite involved. Majority of these patients presented at an advanced stage (advanced T stage - 71.8% and node positive - 62.2%). The majority of the patients received curative-intent treatment (65.4%). The OS at 3 years for these HNSCC patients with coexisting HIV, HBV, and HCV infection was 60%, 62.6%, and 57.5%, respectively, and their DSS at 3 years was 58.8%, 78.6%, and 53.8%, respectively. Conclusions: Seropositive patients with HNSCC often present in the advanced stage but have a good survival if treated appropriately.